Service

Our Services

Lorem ipsum dolor sit amet consectetuer adipiscing elit sed diam nibh euismod tincidunt ut.

PrismGene® monoclonal antibody (mAb) production services include:

1. Recombinant protein and antibody expression

  • Gene codon optimization
  • Plasmid design and construction
  • E. coli expression system
  • Yeast expression system
  • Baculovirus/ insect cell expression system
  • Mammalian cells (transient or stable expressions)
  • Stable single cell clone and protein production
  • Fc fusion proteins

2. Monoclonal antibody (mAb) process development

  • Single cell line cloning
  • Fed-batch animal cell culture and fermentation process development
  • Antibody purification process development and scale-up
  • Antibody purification (Protein A, G, L affinity chromatography, IEX, SEC, HIC, HPLC)
  • Upstream and downstream process integration and scale up

Multiple and flexible options of transient expression and stable expression technology are provided for different projects or different research phases.

PrismGene® provides the latest AI-assisted antibody discovery service and state-of-the-art antibody purification technology including affinity chromatography (AC), IMAC, ion exchange (IEX), gel filtration (SEC), hydrophobic interaction (HIC), and combination, process integration, optimization and scale-up.

  • AI-assisted monoclonal antibody (mAb) discovery,  bispecific antibody (bsAb) design and development 
  • Plasmid and expression vector design
  • Multiple antibody expression platforms (E. coli, yeast, mammalian cells, hybridoma)
  • Antibody analysis (BLI, SPR, KD, IC50, EC50) and functional characterization (ADCC, ADCP, CDC
  • Fc fusion protein and nanobody (Nb) design and production
  • Nonnatural amino acid-containing antibody design and production

PrismGene® provides multiple proprietary antibody expression platforms to meet various demands of different unique antibody. Multiple E. coli expression systems can obtain the protein in 1-2 weeks at low cost and high yield. Our yeast expression system can provide high-yield bulk eukaryotic proteins with low cost culture condition. Our mammalian cell expression systems (CHO, HEK293, Hybridoma) offer antibody with high-quality with full or better functions.

  • Target & Epitope Prediction: AI tools trained on immunoinformatic data predict immunodominant regions on target proteins, identifying high-value epitopes and improving hit rates during early screening.  
  • Structure & Binding Prediction: Deep-learning models (such as AlphaFold and protein language models) predict 3D structures at atomic resolution—including difficult-to-model regions like the CDR H3 loop—to optimize antigen-antibody binding affinity and specificity. 
  • Generative Sequence Design: Instead of sorting through millions of library variants in the lab, generative AI models design novel antibody sequences in silico tailored to exact functional properties, stability, and humanized requirements. 
  • Affinity Maturation & Engineering: Protein language models and reinforcement learning suggest targeted mutations that boost binding strength while minimizing off-target interactions.
  • Developability & Liability Assessment: Computational models screen candidate sequences early for aggregation risks, thermal stability, solubility, and high-concentration viscosity, cutting down late-stage failure rates. 
  • Advanced Modalities (BsAbs & ADCs): For complex formats like bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs), AI optimizes linker design, heterodimer pairing, drug-to-antibody ratios (DAR), and spatial geometry to balance potency and safety.
  • Closed-Loop Discovery (AI + Wet-Lab): AI models generate candidate libraries, laboratory high-throughput platforms (such as automated expression and surface plasmon resonance) test them, and the resulting data loops back to retrain and refine the AI for subsequent rounds.  

 
Biochemical Assays:
  • Enzyme Assays: Measure the catalytic activity of enzymes (e.g., kinases, phosphatases, proteases, deacetylases) and test how compounds inhibit or stimulate them. Examples include kinase phosphorylation assays and HDAC/sirtuin assays. 

  • Immunoassays: Utilize specific antibody-antigen recognition to detect and quantify proteins, hormones, or viral antigens, Enzyme-Linked Immunosorbent Assay (ELISA). 

  • Ligand Binding and Protein-Protein Interaction Assays: Evaluate the affinity (KD), specificity, and binding kinetics between a protein and a small molecule, peptide, or macromolecular complex. Subtypes include radioligand binding and FRET (Fluorescence Resonance Energy Transfer) interaction assays. 

Cell-Based Assays

  • Viability and Cytotoxicity Assays: Assess whether a compound promotes cell survival, impairs metabolic health, or induces cell death. The methods include ATP-based luminescence, MTT, and resazurin reduction assays, etc. 
  • Cell Proliferation Assays: Measure the rate of cell division and growth over time using markers like BrdU incorporation or Ki-67 staining. 

  • Reporter Gene Assays: Quantify transcriptional activation or signal transduction by linking a promoter or pathway to a reporter enzyme, such as luciferase or Green Fluorescent Protein (GFP).  

  • Apoptosis and Cell Cycle Assays: Evaluate programmed cell death pathways and shifts in cell cycle phases via flow cytometry or fluorescent staining such as ADCC, ADCP, CDC. 

  • Functional and Phenotypic Assays: Monitor dynamic cellular events such as calcium flux, electrophysiology, sub-cellular localization, cell migration, and high-content imaging.
1. Core components & technologies
  • Miniaturized Assay Formats: Uses high-density microtiter plates (96, 384, 1,536, or up to 3,456 wells) to reduce reagent volumes, lower costs, and speed up processing.
  • Robotics & Liquid Handling: Automated workstations and robotic arms handle sample transfer, mixing, incubation, and plate movement with minimal human errors
  • Acoustic Liquid Handling: Uses sound waves to eject nanoliter droplets without physical pipettes, preventing cross-contamination and increasing speed.
  • Detection & Readout Systems:
    Employs fluorescence, luminescence, time-resolved fluorescence resonance energy transfer (TR-FRET), fluorescence polarization (FP), and label-free mass spectrometry to measure biochemical or cellular responses.
2. Primary Screening Approaches
  • Target-Based Screening (TDD): Focuses on isolated biological targets (such as GPCRs, kinases, or specific enzymes) to find agonists, antagonists, or inhibitors. 
  • Phenotypic Screening: Evaluates whole cells or multi-cellular models to observe functional or behavioral changes without needing a pre-defined molecular target.
  • Ultra-High-Throughput Screening (uHTS): Scales operations to test upwards of 100,000 to over 1,000,000 compounds per day using advanced industrial automation centers.
3. Data Analysis & AI Integration
  • Quality Control Metrics: Relies on statistical tools like the Z’-factor (scores between 0.5 and 1.0 indicate an excellent, robust assay) and signal-to-noise ratios to filter out false positives.
  • Artificial Intelligence & Machine Learning: Modern HTS workflows integrate graph neural networks (GNNs), deep learning models, and automated image analysis to predict compound-target interactions, handle batch effect corrections, and prioritize hit compounds for hit-to-lead optimization.